Bind Lands Nanoparticle Development Deal With Pfizer
This article was originally published in The Pink Sheet Daily
Executive Summary
The nanoparticle biotech has signed an agreement with Pfizer to develop an undisclosed number of small molecules that will use the Accurins technology to make the particles easier to use in hard to treat diseases.
You may also be interested in...
Pfizer Jumps At The Chance To Apply Bind’s Technology To Immuno-Oncology
Bind has agreed to sell all of its assets to Pfizer for $19.75m after filing for bankruptcy in May. An auction is scheduled for July 25 if other bidders come forward.
Nanomedicine: Will It Get Big?
Big drugmakers will be watching closely to see if second-generation nanomed companies can program small particles to pack big pharmaceutical effects. We profile four start-ups that hope to show that they can: Blend Biosciences, Kala Pharma, Qualiber Technologies, and Uroboros Technologies.
BIND Nanotherapy Shows Early Cancer Efficacy In The Clinic
Strong preclinical data for BIND-014, docetaxel-carrying particles engineered using BIND’s Accurin platform, translated into positive results against tumors not usually vulnerable to the cancer drug, the company reported at a late-breaker poster session of the American Association for Cancer Research annual meeting.